CN103370424A - 作为心脏状况药物功效的替代标志物的血载miRNA - Google Patents

作为心脏状况药物功效的替代标志物的血载miRNA Download PDF

Info

Publication number
CN103370424A
CN103370424A CN2011800675783A CN201180067578A CN103370424A CN 103370424 A CN103370424 A CN 103370424A CN 2011800675783 A CN2011800675783 A CN 2011800675783A CN 201180067578 A CN201180067578 A CN 201180067578A CN 103370424 A CN103370424 A CN 103370424A
Authority
CN
China
Prior art keywords
mir
hsa
mirna
level
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800675783A
Other languages
English (en)
Chinese (zh)
Inventor
E.V.罗耶
B.迪金森
A.塞托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viridian Therapeutics Inc
Original Assignee
Miragen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miragen Therapeutics Inc filed Critical Miragen Therapeutics Inc
Publication of CN103370424A publication Critical patent/CN103370424A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
CN2011800675783A 2010-12-15 2011-12-15 作为心脏状况药物功效的替代标志物的血载miRNA Pending CN103370424A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US42345610P 2010-12-15 2010-12-15
US61/423,456 2010-12-15
US201161495220P 2011-06-09 2011-06-09
US61/495,220 2011-06-09
US201161538585P 2011-09-23 2011-09-23
US61/538,585 2011-09-23
PCT/US2011/065120 WO2012083004A2 (en) 2010-12-15 2011-12-15 Blood-borne mirnas as surrogate markers of drug efficacy for cardiac conditions

Publications (1)

Publication Number Publication Date
CN103370424A true CN103370424A (zh) 2013-10-23

Family

ID=45444747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800675783A Pending CN103370424A (zh) 2010-12-15 2011-12-15 作为心脏状况药物功效的替代标志物的血载miRNA

Country Status (7)

Country Link
US (1) US20140024700A1 (enExample)
EP (1) EP2652146A2 (enExample)
JP (1) JP2014507123A (enExample)
CN (1) CN103370424A (enExample)
AU (1) AU2011343719A1 (enExample)
CA (1) CA2818174A1 (enExample)
WO (1) WO2012083004A2 (enExample)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104031987A (zh) * 2014-05-12 2014-09-10 贵州省人民医院 miRNA在心肌纤维化疾病治疗中的应用
CN104306992A (zh) * 2013-11-26 2015-01-28 上海中医药大学附属岳阳中西医结合医院 循环miR-210在高血压早期诊断及靶器官损害预警中的应用
WO2015096659A1 (zh) * 2013-12-27 2015-07-02 江苏命码生物科技有限公司 miRNA-214抑制剂在抑制调节性T细胞中的应用
CN105999302A (zh) * 2016-06-13 2016-10-12 上海市东方医院 一种miRNA-21a抑制剂及在制备延缓心肌梗死的药物中的用途
CN106399473A (zh) * 2016-08-23 2017-02-15 南京大学 检测和评价力量训练效果的miRNA标志物或其组合及其应用
CN106729757A (zh) * 2017-03-08 2017-05-31 复旦大学附属中山医院 miR‑378抑制心肌肥厚和心肌纤维化并诊断心力衰竭的用途
CN107557464A (zh) * 2016-07-02 2018-01-09 上海市公共卫生临床中心 用于干扰素治疗慢性乙型肝炎早期病毒学反应的预测模型及检测试剂盒
CN107881173A (zh) * 2017-11-16 2018-04-06 上海市东方医院 一种miRNA‑21小分子及其用途
CN108004316A (zh) * 2018-01-09 2018-05-08 青岛大学 用于预测急性心肌梗死风险的试剂盒
CN108866177A (zh) * 2018-05-31 2018-11-23 李继承 hsa-miRNA-423-5p和hsa-miRNA-423-5p抑制剂的用途
CN110055322A (zh) * 2019-05-12 2019-07-26 青岛大学 用于急性心肌梗死诊断的循环miRNA标志物及其应用
CN112410414A (zh) * 2020-10-09 2021-02-26 嘉兴市妇幼保健院 孕妇血清外泌体miRNA标志物在制备胎儿先心病早期诊断产品中的应用及试剂盒
CN113943792A (zh) * 2021-11-02 2022-01-18 石河子大学 检测miRNA表达量的试剂在制备诊断或预后哈萨克族高血压的试剂或试剂盒中的应用
CN116726038A (zh) * 2022-03-04 2023-09-12 南京大学 来源于棕榈炭的microRNA或其组合在制备止血药物中的应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
WO2014083081A1 (en) * 2012-11-27 2014-06-05 Centre de Recherche Public de la Santé Compositions and methods for evaluating heart failure
CN103290116B (zh) * 2013-05-16 2016-09-07 南京市妇幼保健院 一种与胎儿先天性心脏病相关的母体血清/血浆miRNA标志物及其应用
US20160251720A1 (en) * 2013-11-01 2016-09-01 The Trustees Of Columbia University In The City New York MicroRNA PROFILES IN HEART FAILURE: METHODS AND SYSTEMS FOR DETECTION AND USE
WO2015175831A1 (en) 2014-05-14 2015-11-19 Ohio State Innovation Foundation Mirna biomarkers for monitoring bone marrow reconstitution
EP3034623A1 (en) * 2014-12-18 2016-06-22 Centro de Investigación Biomédica en Red (CIBER) Method for predicting response to continuous positive air pressure treatment
EP3292213A1 (en) * 2015-05-04 2018-03-14 Academisch Medisch Centrum Biomarkers for the detection of aspirin insensitivity
CN107683341A (zh) * 2015-05-08 2018-02-09 新加坡科技研究局 用于慢性心力衰竭的诊断和预后的方法
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
CN107858419A (zh) * 2017-11-10 2018-03-30 青岛大学 miRNA的应用、应用其的产品及检测方法
US20230288431A1 (en) * 2020-06-08 2023-09-14 National University Corporation Tokai National Higher Education And Research System Use of micro-rna to improve and treat chronic phase cardiac function

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042231A2 (en) * 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
WO2009157204A1 (ja) * 2008-06-27 2009-12-30 学校法人 慶應義塾 バイオマーカーとしてのマイクロｒｎａを用いた婦人科がんの診断・治療選択
CN101643791A (zh) * 2009-09-04 2010-02-10 哈尔滨医科大学 microRNA-328及其反义核苷酸在诊断、防治心脏疾病中的用途
CN101802227A (zh) * 2007-07-18 2010-08-11 科罗拉多大学董事会 非衰竭与衰竭的人心脏中微小rna的差异表达
WO2010091204A1 (en) * 2009-02-04 2010-08-12 Board Of Regents, The University Of Texas System Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders
WO2010130351A1 (en) * 2009-05-15 2010-11-18 Bayer Schering Pharma Ag Micrornas as biomarkers and therapeutic targets for heart failure

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042231A2 (en) * 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
CN101802227A (zh) * 2007-07-18 2010-08-11 科罗拉多大学董事会 非衰竭与衰竭的人心脏中微小rna的差异表达
WO2009157204A1 (ja) * 2008-06-27 2009-12-30 学校法人 慶應義塾 バイオマーカーとしてのマイクロｒｎａを用いた婦人科がんの診断・治療選択
WO2010091204A1 (en) * 2009-02-04 2010-08-12 Board Of Regents, The University Of Texas System Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders
WO2010130351A1 (en) * 2009-05-15 2010-11-18 Bayer Schering Pharma Ag Micrornas as biomarkers and therapeutic targets for heart failure
CN101643791A (zh) * 2009-09-04 2010-02-10 哈尔滨医科大学 microRNA-328及其反义核苷酸在诊断、防治心脏疾病中的用途

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104306992A (zh) * 2013-11-26 2015-01-28 上海中医药大学附属岳阳中西医结合医院 循环miR-210在高血压早期诊断及靶器官损害预警中的应用
US10519441B2 (en) 2013-12-27 2019-12-31 Jiangsu Micromedmark Biotech Co., Ltd. Use of miRNA-214 inhibitor in inhibiting regulatory cells
WO2015096659A1 (zh) * 2013-12-27 2015-07-02 江苏命码生物科技有限公司 miRNA-214抑制剂在抑制调节性T细胞中的应用
CN104031987B (zh) * 2014-05-12 2016-08-31 贵州省人民医院 miRNA在心肌纤维化疾病治疗中的应用
CN104031987A (zh) * 2014-05-12 2014-09-10 贵州省人民医院 miRNA在心肌纤维化疾病治疗中的应用
CN105999302A (zh) * 2016-06-13 2016-10-12 上海市东方医院 一种miRNA-21a抑制剂及在制备延缓心肌梗死的药物中的用途
CN107557464B (zh) * 2016-07-02 2021-06-04 上海市公共卫生临床中心 用于干扰素治疗慢性乙型肝炎早期病毒学反应的预测模型及检测试剂盒
CN107557464A (zh) * 2016-07-02 2018-01-09 上海市公共卫生临床中心 用于干扰素治疗慢性乙型肝炎早期病毒学反应的预测模型及检测试剂盒
CN106399473A (zh) * 2016-08-23 2017-02-15 南京大学 检测和评价力量训练效果的miRNA标志物或其组合及其应用
CN106729757A (zh) * 2017-03-08 2017-05-31 复旦大学附属中山医院 miR‑378抑制心肌肥厚和心肌纤维化并诊断心力衰竭的用途
CN107881173A (zh) * 2017-11-16 2018-04-06 上海市东方医院 一种miRNA‑21小分子及其用途
CN108004316A (zh) * 2018-01-09 2018-05-08 青岛大学 用于预测急性心肌梗死风险的试剂盒
CN108866177A (zh) * 2018-05-31 2018-11-23 李继承 hsa-miRNA-423-5p和hsa-miRNA-423-5p抑制剂的用途
CN108866177B (zh) * 2018-05-31 2021-05-28 李继承 hsa-miRNA-423-5p和hsa-miRNA-423-5p抑制剂的用途
CN110055322A (zh) * 2019-05-12 2019-07-26 青岛大学 用于急性心肌梗死诊断的循环miRNA标志物及其应用
CN112410414A (zh) * 2020-10-09 2021-02-26 嘉兴市妇幼保健院 孕妇血清外泌体miRNA标志物在制备胎儿先心病早期诊断产品中的应用及试剂盒
CN112410414B (zh) * 2020-10-09 2022-07-08 嘉兴市妇幼保健院 孕妇血清外泌体miRNA标志物在制备胎儿先心病早期诊断产品中的应用及试剂盒
CN113943792A (zh) * 2021-11-02 2022-01-18 石河子大学 检测miRNA表达量的试剂在制备诊断或预后哈萨克族高血压的试剂或试剂盒中的应用
CN116726038A (zh) * 2022-03-04 2023-09-12 南京大学 来源于棕榈炭的microRNA或其组合在制备止血药物中的应用

Also Published As

Publication number Publication date
CA2818174A1 (en) 2012-06-21
AU2011343719A1 (en) 2013-04-11
WO2012083004A2 (en) 2012-06-21
US20140024700A1 (en) 2014-01-23
WO2012083004A3 (en) 2012-11-29
EP2652146A2 (en) 2013-10-23
JP2014507123A (ja) 2014-03-27

Similar Documents

Publication Publication Date Title
US20140024700A1 (en) Blood-borne mirnas as surrogate markers of drug efficacy for cardiac conditions
US20160251720A1 (en) MicroRNA PROFILES IN HEART FAILURE: METHODS AND SYSTEMS FOR DETECTION AND USE
US9072765B2 (en) Identification of micro-RNAs involved in post-myocardial infarction remodeling and heart failure
US8513209B2 (en) Micro-RNAS of the MIR-15 family modulate cardiomyocyte survival and cardiac repair
WO2009058818A2 (en) Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
WO2009018492A2 (en) Micro-rnas that control myosin expression and myofiber identity
EP3039156B1 (en) Risk markers for cardiovascular disease in patients with chronic kidney disease
US10772974B2 (en) Compositions and methods for cardiac regeneration
US20170081722A1 (en) Polymorphisms in the pde3a gene
US20140274923A1 (en) Mirnas as a prognostic biomarker in pediatric heart failure
WO2012027557A1 (en) SELECTIVE INHIBITION OF β 1- ADRENERGIC RECEPTORS FOR THE TREATMENT OF PEDIATRIC HEART FAILURE
US20200239957A1 (en) Prediction and treatment of heart failure
US10246711B2 (en) RNAi inhibitors of glucose-6-phosphate dehydrogenase for treating cardiovascular and pulmonary conditions
WO2010117860A2 (en) Microrna signature to predict prognosis in heart failure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131023